Search Results

DalCor Pharmaceuticals announces Dal-GenE-2 confirmatory trial and closing of Series D financing round

DalCor Pharmaceuticals announced the closing of the company’s Series D financing round of $80m USD to conduct the Dal-GenE-2 confirmatory trial in North America under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration.

September 13, 2023

·

3 min read

Business

Dr. David G. Kallend joins DalCor Pharmaceuticals as Chief Scientific Officer

DalCor Pharmaceuticals today announced the appointment of Dr. David G. Kallend as Chief Scientific Officer effective July 1, 2020. Dr. Kallend joins DalCor from The Medicines Company where he held the position of Senior Vice President and Chief Medical Officer.

July 2, 2020

·

2 min read

Business

Diane E. Sullivan joins DalCor Pharmaceuticals as Chief Commercial Officer

DalCor Pharmaceuticals announced the appointment of Diane E. Sullivan as Chief Commercial Officer effective June 1, 2020.

June 8, 2020

·

2 min read

DalCor announces dal-GenE trial continues with final data expected in the first half of 2021

DalCor Pharmaceuticals announced that the independent dal-GenE Data and Safety Monitoring Board recommends the dal-GenE pivotal outcomes trial should continue as planned with no modifications.

July 27, 2020

·

2 min read

Drug Development

DalCor Announces Launch of Dalcetrapib Clinical Trial for COVID-19New dal-COVID Phase 2 proof of concept study results anticipated in Q1 2021

DalCor Pharmaceuticals today announced the initiation of dal-COVID, a Phase 2 proof-of-concept study for dalcetrapib as a potential oral anti-viral treatment for COVID-19.

January 11, 2021

·

2 min read

dal-GenE Phase 3 Cardiovascular Precision Medicine Outcomes Trial Results Published in European Heart Journal

DalCor Pharmaceuticals announced the results of the dal-GenE Phase 3 cardiovascular precision medicine outcomes trial with publication of ‘ Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome.

July 21, 2022

·

5 min read

Business

DalCor Pharmaceuticals Announces Dr. Fouzia Laghrissi-Thode as Chief Executive Officer

Dr. Laghrissi-Thode is currently on the Board of Directors for DalCor.

April 9, 2018

·

2 min read

Drug Development

DalCor Announces Expansion and Accelerated Enrollment of the dal-GenE Clinical Trial

DalCor today announced that the company will increase enrollment in its ongoing Phase 3 clinical trial of dalcetrapib from 5000 to 6000 patients.